Skip to Content

Palivizumab Pregnancy and Breastfeeding Warnings

Palivizumab is also known as: Synagis

Medically reviewed on June 5, 2017

Palivizumab Pregnancy Warnings

Animal studies have not been reported. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug is not indicated for adult use.

AU TGA pregnancy category: Not assigned
US FDA pregnancy category: C

Comment:
-It is not known whether this drug can cause fetal harm when administered to a pregnant woman or could affect reproductive capacity.

See references

Palivizumab Breastfeeding Warnings

The manufacturer makes no recommendation regarding use during lactation.

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

Comments:
-This drug is not indicated for adult use.
-The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Synagis (palivizumab)." Ross Product Division Pharmaceuticals, Columbus, OH.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. "Product Information. Synagis (palivizumab)." Ross Product Division Pharmaceuticals, Columbus, OH.
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide